Results 1 to 10 of about 11,907 (228)

SERPINA1 gene regulates the tumorigenesis and progression of breast cancer through PI3K/AKT signaling pathway and tumor immune microenvironment [PDF]

open access: yesScientific Reports
This study aims to reveal the influence of SERPINA1 gene on the development, prognosis evaluation and immune environment changes of breast cancer. Cell lines with differential SERPINA1 expression were constructed.
Chuqi Lei   +7 more
doaj   +3 more sources

SERPINA1 is a new frontier in cancer immunotherapy and drug targeting by pan-cancer analysis [PDF]

open access: yesDiscover Oncology
Background The immune response can be modulated by autophagy to alter tumor growth. SERPINA1 is not only an autophagy-related protein but also a serine protease inhibitor with the potential for immunotherapy and targeted drug therapy.
Chen Fu   +3 more
doaj   +3 more sources

Bioinformatic analysis of serpina1 expression in papillary thyroid carcinoma and its potential association with Hashimoto's thyroiditis [PDF]

open access: yesDiscover Oncology
Purpose Previous studies have suggested that SERPINA1 may promote a better prognosis in papillary thyroid carcinoma (PTC) along with Hashimoto's thyroiditis (HT).
Xiuyuan Du, Wanjun Chen
doaj   +3 more sources

Characterization of a novel SERPINA1 variant carrying two missense mutations: molecular mechanisms and functional impact [PDF]

open access: yesOrphanet Journal of Rare Diseases
Alpha 1-Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, which encodes the Alpha 1-Antitrypsin (AAT) protein.
Celine Leon   +25 more
doaj   +3 more sources

SERPINA1 methylation as a novel diagnostic marker for early-stage papillary thyroid carcinoma via MAPK6-AKT/mTOR pathway [PDF]

open access: yesClinical Epigenetics
Most thyroid nodules can be diagnosed preoperatively by ultrasonography and fine-needle aspiration biopsy. However, accurately differentiating between benign nodules or indolent thyroid tumors and aggressive thyroid cancers remains a significant clinical
Junjie Li   +7 more
doaj   +3 more sources

Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression. [PDF]

open access: yesPLoS ONE
SERPINA1 Z and PNPLA3 G alleles are the most potent genetic risk modifiers in chronic liver disease (CLD) progression. We aimed to test the impact of concomitant carriage of these variants on the progression of CLDs of various aetiology.
Mikolas Holinka   +13 more
doaj   +3 more sources

Altered polyadenylation site usage in SERPINA1 3’UTR in response to cellular stress affects A1AT protein expression [PDF]

open access: yesScientific Reports
Alternative polyadenylation results in different 3’ isoforms of messenger RNA (mRNA) transcripts. Alternative polyadenylation in the 3’ untranslated region (3’UTR) can alter RNA localization, stability and translational efficiency.
F. N. U. Jiamutai   +5 more
doaj   +3 more sources

CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling

open access: yesCell Death Discovery
Colorectal cancer (CRC) is a highly malignant carcinoma associated with poor prognosis, and metastasis is one of the most common causes of death in CRC. Serpin Family A Member 1 (SERPINA1) is a serine protease inhibitor from the Serpin family.
Yiming Ma   +7 more
doaj   +2 more sources

SERPINA1 as a Shared Biomarker in Periodontitis and Oral Squamous Cell Carcinoma [PDF]

open access: yesInternational Dental Journal
Objective: Periodontitis (PD) and oral squamous cell carcinoma (OSCC) frequently co‑occur in clinical populations. However, shared molecular determinants that could support risk assessment across diseases remain insufficiently defined.
Jingkun Zhang   +4 more
doaj   +2 more sources

SERPINA1 drives TACE resistance in hepatocellular carcinoma by competitively binding ITGB3 to block ITCH-mediated ubiquitination and degradation. [PDF]

open access: yesCell Oncol (Dordr)
Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-to-advanced hepatocellular carcinoma (HCC), but post-TACE resistance remains a major clinical challenge.
Zhang L   +6 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy